Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Teneligliptin Saga: Brands Bazaar, Surging Volumes

Executive Summary

More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.

You may also be interested in...



Competition Piles Up: 100 Teneligliptin Brands Now In India

A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.

BI-Lupin Deal To Up The Heat In Indian DPP-4 Market

Innovator firms continue to tap into the marketing muscle of domestic companies as they vie for a bigger share of India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market.

Permanent Indian Bar Against Glenmark’s Sitagliptin Copies

An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel